Israel - English - Ministry of Health

genmedix , israel - methylprednisolone as hemisuccinate - lyophilized powder for solution for injection or infusion - methylprednisolone as hemisuccinate 1 g/vial - methylprednisolone - methylprednisolone - methylprednisolone mylan is indicated to treat any condition in which iv corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.

Israel - English - Ministry of Health

genmedix , israel - methylprednisolone as hemisuccinate - lyophilized powder for solution for injection or infusion - methylprednisolone as hemisuccinate 500 mg/vial - methylprednisolone - methylprednisolone - methylprednisolone mylan is indicated to treat any condition in which iv corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - prednicarbate (unii: v901lv1k7d) (prednicarbate - unii:v901lv1k7d) - prednicarbate 1 mg in 1 g - prednicarbate cream 0.1% (emollient) is a medium-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. prednicarbate cream 0.1% (emollient) may be used with caution in pediatric patients 1 year of age or older. the safety and efficacy of drug use for longer than 3 weeks in this population have not been established. since safety and efficacy of prednicarbate cream 0.1% (emollient) have not been established in pediatric patients below 1 year of age, its use in this age group is not recommended. prednicarbate cream 0.1% (emollient) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparations.

United States - English - NLM (National Library of Medicine)

fougera pharmaceuticals inc. - prednicarbate (unii: v901lv1k7d) (prednicarbate - unii:v901lv1k7d) - prednicarbate 1.0 mg in 1 g - prednicarbate ointment 0.1% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. prednicarbate ointment 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparations.

United States - English - NLM (National Library of Medicine)

hikma pharmaceutical - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - prednisone 5 mg - prednisone tablets, usp are indicated in the following conditions: - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis - collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - prednisone 5 mg - prednisone tablets, usp are indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis. 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic derznatomyositis

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - prednisone 20 mg - prednisone tablets are indicated in the following conditions: endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis; epicondylitis. collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythemato

United States - English - NLM (National Library of Medicine)

stat rx usa - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone oral solution is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus eryt

United States - English - NLM (National Library of Medicine)

rebel distributors corp - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone oral solution is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematos

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone syrup is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus